Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review
Academic Article
Publication Date:
2021
abstract:
• In the current systematic review, over 800 articles were screened and 14 articles were included in the quantitative analysis. • Based on mostly phase III trials with a low risk of bias, beneficial effects on health-related quality of life (HRQOL) outcomes have been described for abiraterone acetate and docetaxel in the metastatic castration-sensitive prostate cancer setting, for apalutamide and enzalutamide in the nonmetastatic castration-resistant prostate cancer setting, and abiraterone acetate, enzalutamide, and radium-223 in the metastatic castration-resistant prostate cancer setting. • Efforts should be undertaken to optimize comparability between HRQOL outcomes based on different validated questionnaires as well as integration of supportive care regimens.
Iris type:
1.1 Articolo in rivista
Keywords:
Advanced prostate cancer; Castration-resistant prostate cancer; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; European Quality of Life 5-Dimensions; Functional Assessment of Cancer Therapy-Prostate; Health-related quality of life; Metastatic prostate cancer
List of contributors:
Kretschmer, A.; Ploussard, G.; Heidegger, I.; Tsaur, I.; Borgmann, H.; Surcel, C.; Mathieu, R.; de Visschere, P.; Valerio, M.; van den Bergh, R. C. N.; Marra, G.; Thibault, C.; Ost, P.; Gandaglia, G.; Tilki, D.
Published in: